Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 consolidated financial results announced for periods ended September 30, 2026.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 consolidated financial results announced for periods ended September 30, 2026
- Detailed revenue, earnings, guidance and operating metrics contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $3.44B, up 12%, supported by CF growth and diversification into CASGEVY, JOURNAVX, and PALSONIFY
- FY2026 revenue guidance raised to $13.15B-$13.25B, with CASGEVY and JOURNAVX expected to contribute at least $500M combined
- Crinetics acquisition added PALSONIFY, generated $10.1M in September revenue, and established Vertex’s rare-endocrine commercial platform
- Acquisition costs of $502M reduced GAAP net income to $654M, while non-GAAP net income remained $1.21B
- Cash and securities declined to $9.8B after $9.0B acquisition and buyback spending, partly offset by $4.5B term borrowing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.